GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » RxSight Inc (NAS:RXST) » Definitions » EPS (Diluted)

RxSight (RxSight) EPS (Diluted) : $-1.42 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is RxSight EPS (Diluted)?

RxSight's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.25. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.42.

RxSight's EPS (Basic) for the three months ended in Dec. 2023 was $-0.25. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.42.

RxSight's EPS without NRI for the three months ended in Dec. 2023 was $-0.25. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-1.38.

During the past 3 years, the average EPS without NRIGrowth Rate was 9.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 5 years, RxSight's highest 3-Year average EPS without NRI Growth Rate was 32.10% per year. The lowest was 9.80% per year. And the median was 20.95% per year.


RxSight EPS (Diluted) Historical Data

The historical data trend for RxSight's EPS (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

RxSight EPS (Diluted) Chart

RxSight Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EPS (Diluted)
1.39 0.18 -3.57 -2.41 -1.41

RxSight Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.56 -0.42 -0.40 -0.35 -0.25

Competitive Comparison of RxSight's EPS (Diluted)

For the Medical Devices subindustry, RxSight's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


RxSight's PE Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, RxSight's PE Ratio distribution charts can be found below:

* The bar in red indicates where RxSight's PE Ratio falls into.



RxSight EPS (Diluted) Calculation

EPS (Diluted) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Diluted EPS takes into account all of the outstanding dilutive securities that could potentially be exercised (such as stock options and convertible preferred stock) and shows how such an action would impact earnings per share.

RxSight's Diluted EPS for the fiscal year that ended in Dec. 2023 is calculated as

Diluted EPS (A: Dec. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-48.608-0)/34.455
=-1.41

RxSight's Diluted EPS for the quarter that ended in Dec. 2023 is calculated as

Diluted EPS (Q: Dec. 2023 )=(Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-9.177-0)/35.978
=-0.26

EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


RxSight  (NAS:RXST) EPS (Diluted) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


RxSight EPS (Diluted) Related Terms

Thank you for viewing the detailed overview of RxSight's EPS (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


RxSight (RxSight) Business Description

Traded in Other Exchanges
N/A
Address
100 Columbia, Aliso Viejo, CA, USA, 92656
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery.
Executives
Ilya Goldshleger officer: Chief Operating Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Eric Weinberg officer: Chief Commercial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shweta Maniar director C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Jesse Anderson Corley director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Kurtz Ronald M Md director, officer: See Remarks C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert Keith Warner director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Shelley B Thunen officer: Chief Financial Officer C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Bakker Juliet Tammenoms director LONGITUDE CAPITAL MANAGEMENT CO., LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Tamara Fountain director C/O RXSIGHT, INC., 100 COLUMBIA, ALISO VIEJO CA 92656
Robert J Palmisano director 110 HARTWELL AVENUE, LEXINGTON MA 02173
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Julie Andrews director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Rajeev M. Shah 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ra Capital Management, L.p. 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116